✦ LIBER ✦

Novel treatments for irritable bowel syndrome

Book ID: 120862626
Publisher: Adis International Limited (now part of Wolters Kluwer Health)
Year: 2002
Weight: 139 KB
Volume: &NA;
Category: Article
ISSN: 1173-8324
DOI: 10.2165/00128413-200213520-00003

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Novel serotonin type 3 receptor partial

Novel serotonin type 3 receptor partial agonists for the potential treatment of irritable bowel syndrome

✍ David D. Manning; Christopher L. Cioffi; Alexander Usyatinsky; Kevin Fitzpatrick 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 474 KB

Serotonin type 3 (5-HT(3)) receptor partial agonists are being targeted as potential new drugs for the treatment of irritable bowel syndrome (IBS). Two new chemical series bearing indazole and indole cores have exhibited nanomolar binding affinity for the h5-HT(3)A receptor. A range of partial agoni

Linaclotide, Novel Therapy for the Treat

Linaclotide, Novel Therapy for the Treatment of Chronic Idiopathic Constipation and Constipation-Predominant Irritable Bowel Syndrome

✍ Maria I. Vazquez-Roque, Ernest P. Bouras 📂 Article 📅 2013 🏛 Springer Healthcare Communications 🌐 English ⚖ 964 KB

PGN 1091, a novel 5-HT2B receptor antagn

PGN 1091, a novel 5-HT2B receptor antagnist for the treatment of irritable bowel syndrome

✍ Borman, Richard; Oxford, Alec; Denny, Sarah; Sykes, Andrew; Samra, Satinder; Woo 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 258 KB

Su1988 Novel Therapeutic Approaches for

Su1988 Novel Therapeutic Approaches for Treatment of Irritable Bowel Syndrome Using the Multi-Herbal Drug STW 5

✍ Nieber, Karen; Voss, Ulrike; Hoser, Stefanie; Michael, Sebastian; Abdel-Aziz, He 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 114 KB

The use of novel promotility and prosecr

The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation

✍ Jeremy D. Gale 📂 Article 📅 2009 🏛 Springer Healthcare Communications 🌐 English ⚖ 217 KB

ChemInform Abstract: Design and Synthesi

ChemInform Abstract: Design and Synthesis of Piperazinylpyridine Derivatives as Novel 5-HT1A Agonists/5-HT3 Antagonists for the Treatment of Irritable Bowel Syndrome (IBS).

✍ Akira Asagarasu; Teruaki Matsui; Hiroyuki Hayashi; Satoru Tamaoki; Yukinao Yamau 📂 Article 📅 2009 🏛 John Wiley and Sons ⚖ 15 KB 👁 2 views